Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
项目 2:靶向信号网络克服胰腺癌的治疗耐药性
基本信息
- 批准号:10629064
- 负责人:
- 金额:$ 49.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-06 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffectAntibodiesAutomobile DrivingAutophagocytosisBlocking AntibodiesCA-19-9 AntigenCell CompartmentationCell ProliferationCell membraneCellsChemoresistanceClinicalCoculture TechniquesCombined Modality TherapyCommon CarcinomaComplexCytokine SignalingDataDiagnosisDiseaseDisease ResistanceEpidermal Growth Factor ReceptorEpithelial CellsEpitheliumEpitopesFamilyFibroblastsGenesGeneticGenetically Engineered MouseGrowthHeterogeneityHumanIL6 geneImmuneImmune checkpoint inhibitorInterceptKRAS2 geneKineticsLIF geneMalignant NeoplasmsMalignant neoplasm of pancreasMapsMediatingMediatorMethodologyMethodsModelingMolecularMusMutationOrganoidsPancreasPancreatic Ductal AdenocarcinomaParacrine CommunicationPathway interactionsPatientsPhenotypePlayPolysaccharidesPost-Translational Protein ProcessingProductionProteinsReceptor Protein-Tyrosine KinasesRefractoryResidual stateResistanceResistance developmentResolutionRoleSTAT3 geneSignal PathwaySignal TransductionSpecimenStromal CellsTP53 geneTherapeuticTimeTissuesTumor PromotionWorkbiobankcancer cellcell typecheckpoint inhibitionchemotherapyconventional therapycytokineexperimental studyglycosylationin vivoleukemia inhibitory factor receptorloss of functionmouse modelneoplastic cellnovelorganoid transplantationpancreatic ductal adenocarcinoma modelpancreatic tumorigenesisparacrinepharmacologicpreemptresponsesuccesstargeted treatmenttherapy resistanttreatment responsetreatment strategytumortumor growthtumor microenvironmenttumor-immune system interactionstumorigenesis
项目摘要
PROJECT SUMMARY – Project 2: Signaling
Pancreatic ductal adenocarcinoma (PDA) is most commonly diagnosed at late stages, at which time the disease
is refractory to most conventional treatment options. Identifying therapeutic strategies that pre-empt the
development of resistance and achieve durable tumor control has been hampered by the enormous complexity
of the paracrine signaling network in PDA. STAT3 is a major node in this resistance network. The Hunter lab has
shown that production of leukemia inhibitory factor (LIF) by cancer associated fibroblasts (CAFs) is a major driver
of STAT3 signaling in tumor cells and promotes chemoresistance. Further, they have shown that LIF and the
related cytokines IL6 and OSM may also play a role in STAT3 signaling in the immune microenvironment (IME).
In Aim 1, the team will investigate the extent to which induction of STAT3 signaling by these cytokines contributes
to tumor growth and therapeutic resistance. High-resolution spatial profiling and single-cell approaches will be
used to delineate the cell type-specific alterations in STAT3 activation using syngeneic orthotopic models of PDA
following treatment with chemotherapy and blockade of LIF, IL6, and/or OSM, which will be corroborated with
the colocalization of cytokines and STAT3 signaling in human patient specimens. As LIF can activate several
pro-survival pathways, the importance of STAT3-dependent and -independent mechanisms to PDA growth and
chemoresistance will be determined. In addition to chemotherapy, the ability of cytokine blockade to potentiate
immune checkpoint inhibition (ICI) will be investigated. Further, the team has discovered that aberrant
glycosylation can also modulate the STAT3 pathway. Elevation of the glycan CA19-9 in organoids and in vivo
resulted in increased STAT3 signaling in both the epithelial and stromal compartments. In Aim 2, the mechanism
by which CA19-9 elevation activates STAT3 will be determined and the role of this signaling pathway in
chemoresistance will be dissected in a cell type-specific manner using a novel organoid co-culture platform and
a first of its kind genetically engineered mouse model with pancreas-specific KRAS and TRP53 mutations and
inducible CA19-9 expression. In addition to STAT3, CA19-9 elevation promotes receptor tyrosine kinase
signaling, including activation of the EGFR pathway, which also drives chemoresistance. However, inhibition of
either pathway has yielded limited clinical success. The team’s preliminary studies have revealed correlations
between elevated CA19-9, resistance to chemotherapy, and induction of autophagy, a pathway known to
mediate resistance to both chemotherapeutics and targeted therapies. Therefore, experiments proposed in Aim
3 will systematically dissect how CA19-9 modulation of STAT3, EGFR, and autophagy contribute to therapeutic
resistance. It is important to note that most previous mouse studies on these resistance pathways have been
performed in the absence of CA19-9 and that >90% of PDA patients are CA19-9 positive. Advanced organoid
methodologies will be used to investigate both genetic and pharmacologic perturbation of these pathways,
culminating in in vivo explorations of the efficacies of combination treatment strategies in CA19-9-positive PDA.
项目概要-项目2:信号
胰腺导管腺癌(PDA)最常在晚期诊断,此时疾病
对大多数常规治疗方案是难治的。确定预先预防的治疗策略
发展耐药性和实现持久的肿瘤控制受到巨大复杂性的阻碍,
旁分泌信号网络。STAT 3是该电阻网络中的主要节点。亨特实验室
显示由癌症相关成纤维细胞(CAF)产生的白血病抑制因子(LIF)是一个主要驱动因素,
STAT 3信号在肿瘤细胞和促进化疗耐药性。此外,他们还表明,LIF和
相关的细胞因子IL 6和OSM也可能在免疫微环境(IME)中的STAT 3信号传导中起作用。
在目标1中,研究小组将研究这些细胞因子诱导STAT 3信号传导的程度,
与肿瘤生长和治疗耐药性有关。高分辨率空间剖面和单细胞方法将是
用于使用PDA的同基因原位模型描绘STAT 3活化中的细胞类型特异性改变
在用化疗和LIF、IL 6和/或OSM的阻断治疗后,这将用
细胞因子和STAT 3信号在人类患者标本中的共定位。由于LIF可以激活多个
促生存途径,STAT 3依赖和非依赖机制对PDA生长的重要性,
将测定化学抗性。除化疗外,细胞因子阻断增强
将研究免疫检查点抑制(ICI)。此外,研究小组还发现,
糖基化也可以调节STAT 3途径。类器官和体内聚糖CA 19 -9的升高
导致上皮和基质区室中STAT 3信号传导增加。在目标2中,
CA 19 -9升高激活STAT 3的信号通路,以及该信号通路在
将使用新型类器官共培养平台以细胞类型特异性方式剖析化学抗性,
第一个具有胰腺特异性KRAS和TRP 53突变的基因工程小鼠模型,
可诱导CA 19 -9表达。除了STAT 3,CA 19 -9升高促进受体酪氨酸激酶
信号传导,包括EGFR途径的激活,这也会导致化疗耐药性。然而,抑制
两种途径都产生了有限的临床成功。该团队的初步研究揭示了
CA 19 -9升高、化疗耐药和诱导自噬之间的关系,自噬是一种已知的
介导对化疗药物和靶向治疗的抗性。因此,Aim中提出的实验
3将系统地剖析CA 19 -9对STAT 3,EGFR和自噬的调节如何有助于治疗
阻力值得注意的是,大多数以前对这些抗性途径的小鼠研究都是
在不存在CA 19 -9的情况下进行,并且>90%的PDA患者是CA 19 -9阳性。高级类器官
方法学将用于研究这些途径的遗传和药理学扰动,
最终在体内探索联合治疗策略在CA 19 -9阳性PDA中的功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TONY R. HUNTER其他文献
TONY R. HUNTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TONY R. HUNTER', 18)}}的其他基金
Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
克服胰腺导管腺癌的治疗耐药机制
- 批准号:
10629062 - 财政年份:2023
- 资助金额:
$ 49.76万 - 项目类别:
Histidine phosphorylation as a new target for cancer therapy
组氨酸磷酸化作为癌症治疗的新靶点
- 批准号:
10680390 - 财政年份:2019
- 资助金额:
$ 49.76万 - 项目类别:
Histidine phosphorylation as a new target for cancer therapy
组氨酸磷酸化作为癌症治疗的新靶点
- 批准号:
10228707 - 财政年份:2019
- 资助金额:
$ 49.76万 - 项目类别:
Histidine phosphorylation as a new target for cancer therapy
组氨酸磷酸化作为癌症治疗的新靶点
- 批准号:
10020348 - 财政年份:2019
- 资助金额:
$ 49.76万 - 项目类别:
Histidine phosphorylation as a new target for cancer therapy
组氨酸磷酸化作为癌症治疗的新靶点
- 批准号:
10450680 - 财政年份:2019
- 资助金额:
$ 49.76万 - 项目类别:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
看不见的磷酸化蛋白质组:研究组氨酸磷酸化的新工具
- 批准号:
9228357 - 财政年份:2015
- 资助金额:
$ 49.76万 - 项目类别:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
看不见的磷酸化蛋白质组:研究组氨酸磷酸化的新工具
- 批准号:
9437683 - 财政年份:2015
- 资助金额:
$ 49.76万 - 项目类别:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
看不见的磷酸化蛋白质组:研究组氨酸磷酸化的新工具
- 批准号:
9017975 - 财政年份:2015
- 资助金额:
$ 49.76万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 49.76万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 49.76万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 49.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 49.76万 - 项目类别:
Studentship